JP7791546B2 - 眼遺伝子送達のためのａａｖベクター変異体 - Google Patents

眼遺伝子送達のためのａａｖベクター変異体

Info

Publication number
JP7791546B2
JP7791546B2 JP2022525579A JP2022525579A JP7791546B2 JP 7791546 B2 JP7791546 B2 JP 7791546B2 JP 2022525579 A JP2022525579 A JP 2022525579A JP 2022525579 A JP2022525579 A JP 2022525579A JP 7791546 B2 JP7791546 B2 JP 7791546B2
Authority
JP
Japan
Prior art keywords
seq
aav
cells
capsid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504773A (ja
JP2023504773A5 (https=
Inventor
クラインローゲル，ソニア
デイビッド，アナンド
バニング，ヒルデガルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medizinische Hochschule Hannover
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Publication of JP2023504773A publication Critical patent/JP2023504773A/ja
Publication of JP2023504773A5 publication Critical patent/JP2023504773A5/ja
Application granted granted Critical
Publication of JP7791546B2 publication Critical patent/JP7791546B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022525579A 2019-10-31 2020-11-02 眼遺伝子送達のためのａａｖベクター変異体 Active JP7791546B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19206603.3 2019-10-31
EP19206603 2019-10-31
PCT/EP2020/080704 WO2021084133A1 (en) 2019-10-31 2020-11-02 Aav vector variants for ocular gene delivery

Publications (3)

Publication Number Publication Date
JP2023504773A JP2023504773A (ja) 2023-02-07
JP2023504773A5 JP2023504773A5 (https=) 2023-11-10
JP7791546B2 true JP7791546B2 (ja) 2025-12-24

Family

ID=68426130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525579A Active JP7791546B2 (ja) 2019-10-31 2020-11-02 眼遺伝子送達のためのａａｖベクター変異体

Country Status (9)

Country Link
US (1) US12509705B2 (https=)
EP (1) EP4051694B1 (https=)
JP (1) JP7791546B2 (https=)
KR (1) KR20220093163A (https=)
CN (1) CN114729009A (https=)
AU (1) AU2020373326A1 (https=)
CA (1) CA3157464A1 (https=)
IL (1) IL291240A (https=)
WO (1) WO2021084133A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240252679A1 (en) * 2021-05-28 2024-08-01 Shanghai Regenelead Therapies Co., Ltd. Recombinant adeno-associated virus having variant capsid, and application thereof
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
AU2023220219A1 (en) 2022-02-17 2024-09-05 Skyline Therapeutics Limited Recombinant adeno-associated virus with modified aav capsid polypeptides
WO2024191778A1 (en) 2023-03-10 2024-09-19 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
AU2024276934A1 (en) * 2023-05-23 2025-12-18 Innovec Biotherapeutics Adeno-associated virus capsid protein, adeno-associated virus containing same, vector and use thereof
AU2024332181A1 (en) 2023-08-31 2026-02-12 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2025051292A1 (zh) * 2024-01-16 2025-03-13 广州译码基因科技有限公司 提高aav病毒对眼组织感染能力的衣壳蛋白突变体及其应用
CN118459557B (zh) * 2024-01-16 2024-11-22 沈阳兴齐眼药股份有限公司 提高aav病毒视网膜穿透能力的衣壳蛋白突变体及其应用
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2026033140A1 (en) * 2024-08-09 2026-02-12 Revvity Gene Delivery Gmbh Variant aav capsid polypeptides targeting the eye
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018506980A (ja) 2015-02-20 2018-03-15 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 遺伝性眼疾患を治療するための方法及び組成物
WO2019006182A1 (en) 2017-06-30 2019-01-03 The Regents Of The University Of California VIRIONS OF ADENO-ASSOCIATED VIRUSES OF CAPSID VARIANTS AND METHODS OF USE THEREOF
WO2019076856A1 (en) 2017-10-16 2019-04-25 Vigeneron Gmbh AAV VECTORS
WO2019104279A1 (en) 2017-11-27 2019-05-31 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
JP2019518458A (ja) 2016-05-13 2019-07-04 ４ディー モレキュラー セラピューティクス インコーポレイテッド アデノ関連ウイルス変異キャプシドおよびその使用方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284746A (en) 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
ES2308779T3 (es) 1995-07-26 2008-12-01 Astrazeneca Ab Receptores quimericos y metodos para identificar compuestos activos en los receptores de glutamato metabotropico y el uso de tales compuestos en el tratamiento de trastornos y enfermedades neurologicas.
US20040248202A1 (en) 1998-09-03 2004-12-09 Wisconsin Alumni Research Foundation Bacteriorhodopsin/G protein-coupled receptor chimeras
US9284363B2 (en) 2006-07-26 2016-03-15 Case Western Reserve University System and method for controlling G-protein coupled receptor pathways
MY152003A (en) 2008-05-29 2014-08-15 Univ Leland Stanford Junior Cell line, system and method for optical control of secondary messengers
WO2012051599A2 (en) 2010-10-15 2012-04-19 Eos Neuroscience, Inc. Modulation neural pathways
CN105755044A (zh) * 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
EP3029063B1 (en) 2011-06-24 2019-10-16 Arctos Medical AG Light-sensitive chimeric gpcr protein
CA2839938A1 (en) 2011-06-28 2013-01-03 University Of Rochester Photoactivatable receptors and their uses
US20140087463A1 (en) 2012-09-25 2014-03-27 The Washington University Optical control of cell signaling
EP3024497B1 (en) 2013-07-26 2021-01-13 University of Iowa Research Foundation Methods and compositions for treating brain diseases
BR112016017817A2 (pt) 2014-02-06 2017-10-10 Genzyme Corp composições e métodos para o tratamento e a prevenção de degeneração macular
US20170007720A1 (en) 2014-02-21 2017-01-12 University Of Florida Research Foundation, Inc. Methods and compositions for gene delivery to on bipolar cells
GB201403260D0 (en) 2014-02-25 2014-04-09 Univ Manchester Treatment of retinal degeneration using gene therapy
EP4678754A3 (en) 2014-03-11 2026-04-08 Wayne State University A modified mglur6 promoter and methods of use
US11021519B2 (en) * 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
US10533187B2 (en) 2015-03-18 2020-01-14 University Of Florida Research Foundation, Incorporated Methods and compositions for restoration of cone function in BCM
CN105154470A (zh) 2015-07-22 2015-12-16 华东师范大学 一种高效筛查g蛋白-偶联受体表达的融合基因构建方法
AU2017302013B2 (en) 2016-07-29 2022-05-26 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
EP4653537A3 (en) 2016-09-02 2026-01-07 Keio University Rhodopsin gene therapy for regenerating visual function or for preventing deterioration in visual function
US10376265B2 (en) 2017-01-30 2019-08-13 Ethicon Llc Non-magnetic fragmentable tissue compression devices
JP7029160B2 (ja) 2017-11-24 2022-03-03 公立大学法人大阪 新規な光受容タンパク質
WO2020148913A1 (ja) 2019-01-18 2020-07-23 俊英 栗原 網膜疾患の予防および進行抑制、視覚認知行動機能の改善、および視覚機能強化
CN115052988A (zh) 2019-11-18 2022-09-13 伯尔尼大学 用于眼部基因递送的给光型双极细胞特异性启动子
US20240174743A1 (en) 2019-11-29 2024-05-30 Universität Bern Chimeric opsin gpcr proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018506980A (ja) 2015-02-20 2018-03-15 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 遺伝性眼疾患を治療するための方法及び組成物
JP2019518458A (ja) 2016-05-13 2019-07-04 ４ディー モレキュラー セラピューティクス インコーポレイテッド アデノ関連ウイルス変異キャプシドおよびその使用方法
WO2019006182A1 (en) 2017-06-30 2019-01-03 The Regents Of The University Of California VIRIONS OF ADENO-ASSOCIATED VIRUSES OF CAPSID VARIANTS AND METHODS OF USE THEREOF
WO2019076856A1 (en) 2017-10-16 2019-04-25 Vigeneron Gmbh AAV VECTORS
WO2019104279A1 (en) 2017-11-27 2019-05-31 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IOVS，2017年，Vol. 58, No. 14，pp. 6429-6439
YAKUGAKU ZASSHI，2006年，126(11)，pp.1021-1028,

Also Published As

Publication number Publication date
EP4051694C0 (en) 2025-07-02
CN114729009A (zh) 2022-07-08
JP2023504773A (ja) 2023-02-07
CA3157464A1 (en) 2021-05-06
WO2021084133A1 (en) 2021-05-06
EP4051694B1 (en) 2025-07-02
US12509705B2 (en) 2025-12-30
EP4051694A1 (en) 2022-09-07
AU2020373326A1 (en) 2022-06-02
US20240287542A1 (en) 2024-08-29
IL291240A (en) 2022-05-01
KR20220093163A (ko) 2022-07-05

Similar Documents

Publication Publication Date Title
JP7791546B2 (ja) 眼遺伝子送達のためのａａｖベクター変異体
JP6072772B2 (ja) 変異体キャプシドを有するアデノ関連ウイルスビリオンおよびその使用方法
US9849195B2 (en) Methods and compositions for treating brain diseases
CN108347932A (zh) 用于治疗遗传性眼病的方法和组合物
CN105980569A (zh) 重组aav-crumbs同源物组合物及治疗lca-8和进行性rp的方法
CN113564187B (zh) 基于aav的抗血管生成基因递送系统及其用途
CA3096088A1 (en) Compositions and methods for treating macular dystrophy
WO2004050876A1 (fr) Vaccin genique concernant un adenovirus recombinant convenant a la therapie et la prophylaxie de la maladie d'alzheimer, et utilisation correspondante
CN115279400A (zh) 用于跨血脑屏障递送免疫治疗剂以治疗脑癌的方法和组合物
AU2019304569B2 (en) Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
KR20240010489A (ko) 시력 기능 향상을 위한 조성물 및 방법
KR20240023126A (ko) 망막 장애
CN116368228A (zh) 用于治疗眼部疾病的组合物和方法
US20220389450A1 (en) Vector system
US20260091140A1 (en) Gene therapy for foxg1 syndrome
CN112522276B (zh) 一种emc1核苷酸序列及其应用
WO2023005906A1 (zh) 新型腺相关病毒血清型介导的血管生成抑制剂及其应用
CN117337331A (zh) 用于增强视觉功能的组合物和方法
WO2025250853A1 (en) Adeno-associated virus vectors with modified membrane associated accessory protein and methods of use
HK40097011A (zh) 工程化的病毒衣壳及使用方法
KR20240023127A (ko) 망막 장애
TW202434733A (zh) 重組腺相關病毒載體
WO2023285986A1 (en) Kcnv2 gene therapy
CN119894920A (zh) 用于靶向神经系统的新型aav衣壳及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241112

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250128

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251204

R150 Certificate of patent or registration of utility model

Ref document number: 7791546

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150